Allied Market Research
Loading...
0
New
New
2021
Infectious Disease Diagnostic Market

Infectious Disease Diagnostic Market by Product (Assays & Reagents, Instruments, and Software), Disease Type (Hepatitis, Human Immunodeficiency Virus, Influenza, and Others), and Technology (Immunodiagnostics, Clinical Microbiology, Polymerase Chain Reaction, Next Generation Sequencing, and Others): Global Opportunity Analysis and Industry Forecast, 2021–2030

A01681
Pages: 257
Sep 2021 | 8037 Views
   
Author(s) : Linu Dash , Onkar Sumant
Tables: 121
Charts: 46
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • IComes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Infectious Disease Diagnostic Market

Request Now !

Infectious Disease Diagnostic Market Overview: 

The global infectious disease diagnostic market was valued at $23,321.99 million in 2020, and is estimated to reach $39,941.37 million by 2030, growing at a CAGR of 6.8% from 2021 to 2030. Infectious disease diagnosis is defined as a laboratory test, which is executed with the help of skilled technicians and physicians to diagnose infectious diseases. It is a diagnostic procedure in which the causative organism of an infectious disease is characterized and identified. The sample of urine, blood, mucus, or other body fluids are analyzed to provide information about the causative organism by the use of various diagnosis procedure and instruments. 

The COVID-19 outbreak is anticipated to have a positive impact on the growth of the global infectious disease diagnostic market. The COVID-19 pandemic has stressed the healthcare systems in the world and increased the need for the development of diagnostic instruments & diagnostic service centers. Increase in number of COVID-19 cases surged the demand for real time polymerase chain reaction (RT-PCR) test to detect COVID-19.

Growth of the global infectious disease diagnostic market is majorly driven by increase in prevalence of infectious disease such as hepatitis, influenza, COVID-19, & human immuno deficiency virus (HIV); rise in demand for point-of-care diagnostic test; increase in funding from private & government organizations for diagnostic service centers; and advancements in technologies in the field of infectious disease diagnostics. According to the Centers for Disease Control and Prevention (CDC), in 2018, it was reported that approximately 1.7 million infections and 99,000 associated deaths occur every year in American hospitals. Furthermore, surge in demand for point-of-care testing is anticipated to fuel the growth of the infection disease diagnostic market. For instance, in March 2020, Abbott, a global healthcare company, announced the launch of Abbott ID NOW COVID-19 test, which is a molecular point-of-care test used to detect COVID-19 in as little as 5 minutes. In addition, rise in geriatric population fuels the market growth, owing to the fact that aged individuals are more susceptible to infectious diseases. According to the U.S. Food and Drug Administration (FDA), in 2020, it was reported that around 300,000 individuals aged 50 and above are diagnosed with pneumococcal pneumonia, every year. In May 2021, Neuberg Diagnostic, a leading company that offers best-in-class laboratories, launched the clinical laboratory's operation in the U.S. to offer genomic and molecular testing on new generation sequencing technology.

infectious-disease-diagnostic-market-2021-2030

Get more information on this report : Request Sample Pages

In addition, increase in number of medical laboratories, for infectious disease diagnostic testing, anticipate the growth of the market. The Government of India, in 2020, announced the launch of three state-of-the-art high throughput Indian Council of Medical Research labs in Kolkata, Mumbai, and Noida, in order to increase the number of COVID-19 testing capacity.  Apart from COVID-19 tests, these labs are also used for other diagnosis test for infectious diseases such as HIV, hepatitis, tuberculosis and dengue. Furthermore, rise in awareness among individuals for early diagnosis and management of infectious disease, increase in number of information technology system to develop advanced diagnostic devices is expected to provide remunerative opportunities for the expansion of the global infectious disease diagnostic market during the forecast period.

Thus, technological advancements in diagnostic instrument and rise in awareness regarding early diagnosis propel the growth of the market. However, high cost associated with diagnostic instruments and lack of skilled technicians is expected to restrict the market growth during the forecast period.

Infectious Disease Diagnosticmarket Segmentation

The global infectious disease diagnostic market is segmented into product, disease type, technology, and region. By product, the market is categorized into assays & reagents, instruments, and software. 

On the basis of disease type, it is divided into hepatitis, human immunodeficiency virus, influenza, and others. Depending on technology, it is categorized into immunodiagnostics, clinical microbiology, polymerase chain reaction, and next-generation sequencing, and others. 

Infectious Disease Diagnostic Market
By Product

Your browser does not support the canvas element.

Assays and Reagents segment held a dominant position in 2020 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Region-wise, the infectious disease diagnostic market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Segment Review

Depending on product, the assays & reagents segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to increase in R&D activities in the pharmaceutical & biotechnology industry, rise in demand for reagents, and surge in adoption of point-of-care testing. However, the instruments segment is expected to witness considerable growth during the forecast period, owing to surge in number of research laboratories and increase in funds by government &private organizations for development of diagnostic instruments in the pharmaceutical &biotechnology industry.

Infectious Disease Diagnostic Market
By Disease Type

Your browser does not support the canvas element.

Others segment held a dominant position in 2020 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

By disease type, the others segment was the major contributor in 2020, and is expected to maintain its lead during the forecast period, owing to increase in prevalence of healthcare associated infection, rise in the number of surgical procedures and increasing demand for early diagnostic. However, the hepatitis segment is expected to witness considerable growth during the forecast period, due to increase in prevalence of hepatitis, rise in demand for early diagnosis, and development of advanced diagnostic laboratory in the hospital and clinics.

On the basis of technology, the others segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to large number key players offering advanced diagnostic medical devices, increase in demand for DNA analysis, development of novel & innovative PCR tools, and advancement in R&D activities for infectious disease diagnosis. However, the immunodiagnostic segment is expected to witness considerable growth during the forecast period, owing to increase in number of genomic projects, surge in awareness about DNA sequencing, and advancements in R&D for DNA analysis activities.

Infectious Disease Diagnostic Market
By Technology

Your browser does not support the canvas element.

Others segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

North America garnered the major share in the infectious disease diagnostic market in 2020, and is expected to continue to dominate during the forecast period, owing to rise in prevalence of infectious disease, presence of key players, development of the healthcare sector, presence of national clinical laboratories, and advancement in technology for diagnostic instruments in the region. However, Asia-Pacific is expected to register the highest CAGR of 8.5% from 2021 to 2030, owing to increase in prevalence of infectious diseases, rise in demand for early diagnosis, development of healthcare infrastructure, and technological advancement in diagnostic testing.

The key players operating in the global infectious disease diagnostic market include Abbott Laboratories, Becton Dickinson and Company, BioMerieus SA, Bio-Rad Laboratories, Danaher Corporation, F Hoffman-La Roche, Hologic Inc., Luminex Corporation, Qiagen Inc., and Thermo Fisher Scientific Inc.

Infectious Disease Diagnostic Market
By Region

2030
North America 
Europe
Asia-pacific
Lamea

North America was holding a dominant position in 2020 and would continue to maintain the lead over the analysis period.

Get more information on this report : Request Sample Pages

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the infectious disease diagnostic market, and the current trends & future estimations to elucidate imminent investment pockets.
  • It presents a quantitative analysis of the infectious disease diagnostic market from 2021 to 2030 to enable stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the infectious disease diagnostic market based on procedures and services assists to understand the trends in the industry.
  • Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the infectious disease diagnostic market.

Key Market Segments

By Product

  • Assays & Reagents
    • Hepatitis
    • Human Immunodeficiency Virus
    • Influenza
    • Others
  • Instruments
    • Hepatitis
    • Human Immunodeficiency Virus
    • Influenza
    • Others
  • Software
    • Hepatitis
    • Human Immunodeficiency Virus
    • Influenza
    • Others

By Disease Type

  • Hepatitis
  • Human Immunodeficiency Virus
  • Influenza
  • Others

By Technology

  • Immunodiagnostics
  • Clinical Microbiology
  • Polymerase Chain Reaction 
  • Next Generation Sequencing
  • Others 

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players 

  • Abbott Laboratories
  • Becton Dickinson and Company
  • bioMerieus SA
  • Bio-Rad Laboratories
  • Danaher Corporation
  • F Hoffman-La Roche
  • Hologic Inc.
  • Luminex Corporation
  • Qiagen Inc.
  • Thermo Fisher Scientific Inc.
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porter’s five forces analysis
3.4.Top player positioning, 2020
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Increase in prevalence of infection diseases
3.5.1.2.Rise in demand for point-of-care diagnostic testing
3.5.1.3.Surge in number of medical laboratories
3.5.1.4.Rise in awareness among individuals regarding early diagnosis detection

3.5.2.Restraints

3.5.2.1.High cost of diagnostic instruments
3.5.2.2.Lack of skilled professional and trained personnel

3.5.3.Opportunity

3.5.3.1.Development of advanced diagnostic devices by key players

3.5.4.Impact analysis

3.6.Impact analysis of COVID-19 on the infectious disease diagnostic market
3.7.Global COVID-19 Diagnostic market

3.7.1.Market size and forecast, by technology
3.7.2.Market size and forecast, by product
3.7.3.Market size and forecast, by end user
3.7.4.Market size and forecast, by region

CHAPTER 4:INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY PRODUCT

4.1.Overview

4.1.1.Market size and forecast

4.2.Assays & reagents

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region

4.2.2.1.Assays and reagents by disease type

4.2.3.Market analysis, by country

4.3.Instruments

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region

4.3.2.1.Instruments by disease type

4.3.3.Market analysis, by country

4.5.Software

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region

4.5.2.1.Software by disease type

4.5.3.Market analysis, by country

CHAPTER 5:INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY DISEASE TYPE

5.1.Overview

5.1.1.Market size and forecast

5.2.Hepatitis

5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by region
5.2.3.Market analysis, by country

5.3.Human immunodeficiency virus (HIV)

5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast, by region
5.3.3.Market analysis, by country

5.4.Influenza

5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market size and forecast, by region
5.4.3.Market analysis, by country

5.5.Others

5.5.1.Key market trends, growth factors, and opportunities
5.5.2.Market size and forecast, by region
5.5.3.Market analysis, by country

CHAPTER 6:INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY TECHNOLOGY

6.1.Overview

6.1.1.Market size and forecast

6.2.Immunodiagnostics

6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by region
6.2.3.Market analysis, by country

6.3.Clinical microbiology

6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by region
6.3.3.Market analysis, by country

6.4.Polymerase chain reaction

6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by region
6.4.3.Market analysis, by country

6.5.Next-generation sequencing

6.5.1.Key market trends, growth factors, and opportunities
6.5.2.Market size and forecast, by region
6.5.3.Market analysis, by country

6.6.Others

6.6.1.Key market trends, growth factors, and opportunities
6.6.2.Market size and forecast, by region
6.6.3.Market analysis, by country

CHAPTER 7:INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.North America  infectious disease diagnostic  market, by product
7.2.3.North America  infectious disease diagnostic  market, by disease type
7.2.4.North America  infectious disease diagnostic  market, by technology
7.2.5.Market size and forecast, by country

7.2.5.1.U.S.

7.2.5.1.1.U.S. infectious disease diagnostic  market, by product
7.2.5.1.2.U.S. infectious disease diagnostic market, by disease type
7.2.5.1.3.U.S. infectious disease diagnostic market, by technology

7.2.5.2.Canada

7.2.5.2.1.Canada infectious disease diagnostic  market, by product
7.2.5.2.2.Canada infectious disease diagnostic market, by disease type
7.2.5.2.3.Canada infectious disease diagnostic market, by technology

7.2.5.3.Mexico

7.2.5.3.1.Mexico infectious disease diagnostic  market, by product
7.2.5.3.2.Mexico infectious disease diagnostic market, by disease type
7.2.5.3.3.Mexico infectious disease diagnostic market, by technology

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe infectious disease diagnostic  market, by product
7.3.3.Europe infectious disease diagnostic  market, by disease type
7.3.4.Europe infectious disease diagnostic  market, by technology
7.3.5.Market size and forecast, by country

7.3.5.1.Germany

7.3.5.1.1.Germany infectious disease diagnostic  market, by product
7.3.5.1.2.Germany infectious disease diagnostic market, by disease type
7.3.5.1.3.Germany infectious disease diagnostic market, by technology

7.3.5.2.France

7.3.5.2.1.France infectious disease diagnostic  market, by product
7.3.5.2.2.France infectious disease diagnostic market, by disease type
7.3.5.2.3.France infectious disease diagnostic market, by technology

7.3.5.3.UK

7.3.5.3.1.UK infectious disease diagnostic  market, by product
7.3.5.3.2.UK infectious disease diagnostic market, by disease type
7.3.5.3.3.UK infectious disease diagnostic market, by technology

7.3.5.4.Italy

7.3.5.4.1.Italy infectious disease diagnostic  market, by product
7.3.5.4.2.Italy infectious disease diagnostic market, by disease type
7.3.5.4.3.Italy infectious disease diagnostic market, by technology

7.3.5.5.Spain

7.3.5.5.1.Spain infectious disease diagnostic  market, by product
7.3.5.5.2.Spain infectious disease diagnostic market, by disease type
7.3.5.5.3.Spain infectious disease diagnostic market, by technology

7.3.5.6.Rest of Europe

7.3.5.6.1.Rest of Europe infectious disease diagnostic  market, by product
7.3.5.6.2.Rest of Europe infectious disease diagnostic market, by disease type
7.3.5.6.3.Rest of Europe infectious disease diagnostic market, by technology

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Asia-Pacific infectious disease diagnostic  market, by product
7.4.3.Asia-Pacific infectious disease diagnostic  market, by disease type
7.4.4.Asia-Pacific infectious disease diagnostic  market, by technology
7.4.5.Market size and forecast, by country

7.4.5.1.Japan

7.4.5.1.1.Japan infectious disease diagnostic  market, by product
7.4.5.1.2.Japan infectious disease diagnostic market, by disease type
7.4.5.1.3.Japan infectious disease diagnostic market, by technology

7.4.5.2.China

7.4.5.2.1.China infectious disease diagnostic  market, by product
7.4.5.2.2.China infectious disease diagnostic market, by disease type
7.4.5.2.3.China infectious disease diagnostic market, by technology

7.4.5.3.Australia

7.4.5.3.1.Australia infectious disease diagnostic  market, by product
7.4.5.3.2.Australia infectious disease diagnostic market, by disease type
7.4.5.3.3.Australia infectious disease diagnostic market, by technology

7.4.5.4.India

7.4.5.4.1.India infectious disease diagnostic  market, by product
7.4.5.4.2.India infectious disease diagnostic market, by disease type
7.4.5.4.3.India infectious disease diagnostic market, by technology

7.4.5.5.South Korea

7.4.5.5.1.South Korea infectious disease diagnostic  market, by product
7.4.5.5.2.South Korea infectious disease diagnostic market, by disease type
7.4.5.5.3.South Korea infectious disease diagnostic market, by technology

7.4.5.6.Rest of Asia-Pacific

7.4.5.6.1.Rest of Asia-Pacific infectious disease diagnostic  market, by product
7.4.5.6.2.Rest of Asia-Pacific infectious disease diagnostic market, by disease type
7.4.5.6.3.Rest of Asia-Pacific infectious disease diagnostic market, by technology

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.LAMEA infectious disease diagnostic  market, by product
7.5.3.LAMEA infectious disease diagnostic  market, by disease type
7.5.4.LAMEA infectious disease diagnostic  market, by technology
7.5.5.Market size and forecast, by country

7.5.5.1.Brazil

7.5.5.1.1.Brazil infectious disease diagnostic  market, by product
7.5.5.1.2.Brazil infectious disease diagnostic market, by disease type
7.5.5.1.3.Brazil infectious disease diagnostic market, by technology

7.5.5.2.Saudi Arabia

7.5.5.2.1.Saudi Arabia infectious disease diagnostic  market, by product
7.5.5.2.2.Saudi Arabia infectious disease diagnostic market, by disease type
7.5.5.2.3.Saudi Arabia infectious disease diagnostic market, by technology

7.5.5.3.South Africa

7.5.5.3.1.South Africa infectious disease diagnostic  market, by product
7.5.5.3.2.South Africa infectious disease diagnostic market, by disease type
7.5.5.3.3.South Africa infectious disease diagnostic market, by technology

7.5.5.4.Rest of LAMEA

7.5.5.4.1.Rest of LAMEA infectious disease diagnostic  market, by product
7.5.5.4.2.Rest of LAMEA infectious disease diagnostic market, by disease type
7.5.5.4.3.Rest of LAMEA infectious disease diagnostic market, by technology

CHAPTER 8:COMPANY PROFILES

8.1.Abbott Laboratories

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments

8.2.Becton Dickinson and Company

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments

8.3.Biomerieux SA

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.3.6.Key strategic moves and developments

8.4.Bio-Rad Laboratories

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments

8.5.Danaher Corporation

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
1.5.4   Business performance

8.6.F Hoffmon La-Roche

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Product portfolio
8.6.4.Key strategic moves and developments

8.7.Hologic Inc.

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Key strategic moves and developments

8.8.Luminex Corporation

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments

8.9.ThermoFisher Scientific

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance

8.10.Qiagen Inc.

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments

LIST OF TABLES

TABLE 01.COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
TABLE 02.COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
TABLE 03.COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
TABLE 04.COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
TABLE 05.COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
TABLE 06.COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
TABLE 07.COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
TABLE 08.COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
TABLE 09.COVID-19 DIAGNOSTICS MARKET, BY REGION, 2020–2022 ($MILLION)
TABLE 10.INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY PRODUCT, 2020–2030 ($MILLION)
TABLE 11.ASSAYS AND REAGENTS INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 12.INFECTIOUS DISEASE ASSAYS & REAGENTS MARKET, BY DISEASE TYPE, 2020-2030($MILLION)
TABLE 13.INSTRUMENTS INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 14.INFECTIOUS DISEASE INSTRUMENTS MARKET, BY DISEASE TYPE, 2020-2030($MILLION)
TABLE 15.SOFTWARE INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 16.INFECTIOUS DISEASE INSTRUMENTS MARKET, BY DISEASE TYPE, 2020-2030($MILLION)
TABLE 17.GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 18.HEPATITIS INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 19.HUMAN IMMUNODEFICIENCY VIRUS INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 20.INFLUENZA INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 21.OTHERS INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 22.GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020–2030 ($MILLION)
TABLE 23.IMMUNODIAGNOSTICS INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 24.CLINICAL MICROBIOLOGY INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 25.POLYMERASE CHAIN REACTION INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 26.NGS INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 27.OTHERS INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 28.INFECTIOUS DISEASE DIAGNOSTIC  MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 29.NORTH AMERICA  INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 30.NORTH AMERICA  INFECTIOUS DISEASE DIAGNOSTIC  MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 31.NORTH AMERICA  INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 32.NORTH AMERICA  INFECTIOUS DISEASE DIAGNOSTIC  MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 33.U.S. INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 34.U.S. INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 35.U.S. INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 36.CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 37.CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 38.CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 39.MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 40.MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 41.MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 42.EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 43.EUROPE INFECTIOUS DISEASE DIAGNOSTIC  MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 44.EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 45.EUROPE  INFECTIOUS DISEASE DIAGNOSTIC  MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 46.GERMANY INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 47.GERMANY INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 48.GERMANY INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 49.FRANCE INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 50.FRANCE INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 51.FRANCE INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 52.UK INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 53.UK INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 54.UK INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 55.ITALY INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 56.ITALY INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 57.ITALY INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 58.SPAIN INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 59.SPAIN INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 60.SPAIN INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 61.REST OF EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 62.REST OF EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 63.REST OF EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 64.ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 65.ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC  MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 66.ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 67.ASIA-PACIFIC  INFECTIOUS DISEASE DIAGNOSTIC  MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 68.JAPAN INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 69.JAPAN INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 70.JAPAN INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 71.CHINA INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 72.CHINA INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 73.CHINA INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 74.AUSTRALIA INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 75.AUSTRALIA INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 76.AUSTRALIA INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 77.INDIA INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 78.INDIA INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 79.INDIA INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 80.SOUTH KOREA INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 81.SOUTH KOREA INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 82.SOUTH KOREA INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 83.REST OF ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 84.REST OF ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 85.REST OF ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 86.LAMEA INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 87.LAMEA INFECTIOUS DISEASE DIAGNOSTIC  MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 88.LAMEA INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 89.LAMEA  INFECTIOUS DISEASE DIAGNOSTIC  MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 90.BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 91.BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 92.BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 93.SAUDI ARABIA INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 94.SAUDI ARABIA INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 95.SAUDI ARABIA INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 96.SOUTH AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 97.SOUTH AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 98.SOUTH AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 99.REST OF LAMEA INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 100.REST OF LAMEA INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 101.REST OF LAMEA INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 102.ABBOTT: COMPANY SNAPSHOT
TABLE 103.ABBOTT: OPERATING SEGMENTS
TABLE 104.ABBOTT: PRODUCT PORTFOLIO
TABLE 105.BD: COMPANY SNAPSHOT
TABLE 106.BD: OPERATING SEGMENTS
TABLE 107.BD: PRODUCT PORTFOLIO
TABLE 108.BIOMERIEUX SA : SNAPSHOT
TABLE 109.BIOMEREIUX: OPERATING SEGMENTS
TABLE 110.BIOMERIEUX: PRODUCT PORTFOLIO
TABLE 111.BIO-RAD: COMPANY SNAPSHOT
TABLE 112.BIO-RAD: OPERATING SEGMENTS
TABLE 113.BIO-RAD: PRODUCT PORTFOLIO
TABLE 114.DANAHER: COMPANY SNAPSHOT
TABLE 115.DANAHER: OPERATING SEGMENTS
TABLE 116.DANAHER: PRODUCT PORTFOLIO
TABLE 117.ROCHE: COMPANY SNAPSHOT
TABLE 118.ROCHE: PRODUCT PORTFOLIO
TABLE 119.HOLOGIC: COMPANY SNAPSHOT
TABLE 120.HOLOGIC: OPERATING SEGMENTS
TABLE 121.HOLOGIC: PRODUCT PORTFOLIO
TABLE 122.LUMINEX: COMPANY SNAPSHOT
TABLE 123.LUMINEX: OPERATING SEGMENTS
TABLE 124.LUMINEX: PRODUCT PORTFOLIO
TABLE 125.THERMO FISCHER: COMPANY SNAPSHOT
TABLE 126.THERMO FISCHER: OPERATING SEGMENTS
TABLE 127.THERMO FISCHER: PRODUCT PORTFOLIO
TABLE 128.QIAGEN INC.: COMPANY SNAPSHOT
TABLE 129.QIAGEN: OPERATING SEGMENTS
TABLE 130.QIAGEN: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018–2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018–2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018–2021
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE THREAT OF SUBSTITUTES
FIGURE 09.HIGH THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE ANALYSIS OF ASSAYS AND REAGENTS INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2020–2030 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF INSTRUMENTS INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY,  2020–2030 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF SOFTWARE INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2020–2030 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF HEPATITIS INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2020–2030 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF HUMAN IMMUNODEFICIENCY VIRUS INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2020–2030 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF INFLUENZA INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2020–2030 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF OTHERS INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2020–2030 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF IMMUNODIAGNOSTICS INFECTIOUS DISEASE DIAGNOSTICS MARKET , BY COUNTRY, 2020–2030 (%)
FIGURE 21.COMPARATIVE ANALYSIS OF CLINICAL MICROBIOLOGY INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2020–2030 (%)
FIGURE 22.COMPARATIVE ANALYSIS OF POLYMERASE CHAIN REACTION INFECTIOUS DISEASE DIAGNOSTICS MARKET,  BY COUNTRY, 2020–2030 (%)
FIGURE 23.COMPARATIVE ANALYSIS OF NGS INFECTIOUS DISEASE DIAGNOSTICS MARKET ,  BY COUNTRY, 2020–2030 (%)
FIGURE 24.COMPARATIVE ANALYSIS OF OTHERS INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY,  2020–2030 (%)
FIGURE 25.ABBOTT: NET SALES, 2018–2020 ($MILLION)
FIGURE 26.ABBOTT: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 27.ABBOTT: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 28.BD: NET SALES, 2018–2020 ($MILLION)
FIGURE 29.BD: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 30.BD: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 31.BIOMERIEUX: NET SALES, 2018–2020 ($MILLION)
FIGURE 32.BIOMERIEUX: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 33.BIOMERIEUX: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 34.BIO-RAD: NET SALES, 2018–2020 ($MILLION)
FIGURE 35.BIO-RAD: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 36.BIO-RAD: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 37.DANHER CORPORATION: NET SALES, 2018–2020 ($MILLION)
FIGURE 38.DANHER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 39.DANHER: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 40.LUMINEX: NET SALES, 2018–2020 ($MILLION)
FIGURE 41.THERMO FISCHER: NET SALES, 2018–2020 ($MILLION)
FIGURE 42.THERMO FISCHER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 43.THERMO FISCHER: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 44.QIAGEN: NET SALES, 2018–2020 ($MILLION)
FIGURE 45.QIAGEN: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 46.QIAGEN: REVENUE SHARE BY REGION, 2020 (%)

 
 

Growth of the infectious disease diagnostic market is attributed to factors such as technological advancements in the healthcare sector; rise in prevalence of infectious diseases such as hepatitis, pneumonia, influenza, HIV, & COVID-19; increase in funds from private and government organizations for development of various diagnostic service centers; and rise in awareness about early diagnosis. The infectious disease diagnostic market gains interest of pharmaceutical and biotechnology companies, owing to surge in demand for point-of-care diagnostic testing. This leads to increase in adoption of diagnostic testing for detection of infectious diseases. Moreover, infectious disease diagnostics technology, such as immunodiagnostic testing, polymerase chain reaction, DNA microarray, and DNA sequencing, have gained high traction in the market in recent years, as infectious disease diagnostic tools are used in diagnosis of infectious diseases.

North America is expected to witness the highest growth, in terms of revenue, owing to rise in prevalence of infectious diseases, increase in number of diagnostic tests, and technological advancement of diagnostic instruments in the region.

Asia-Pacific was the second largest contributor to the market in 2020, and is expected to register the fastest CAGR during the forecast period, owing to increase in prevalence of infectious diseases, rise in government initiative for development of advanced diagnostic service, surge in demand for RT-PCR test, and increase in awareness among people for early diagnostic testing.

However, lack of skilled laboratory technicians and high cost associated with diagnostic testing are anticipated to restrain the market growth during the forecast period.

PURCHASE OPTIONS

Start reading instantly ,This Report and over 13000+ thousand more Reports, Available with Avenue Library, T&C*

Call or Email us

U.S.-Canada
Toll-free :
+1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. The total market value of infectious disease diagnostic market is $23,321.99 million in 2020.

A. The forecast period in the report is from 2021 to 2030

A. The market value of infectious disease diagnostic Market in 2021 was $22,181.54 million

A. The base year for the report is 2020.

A. Yes, infectious disease diagnostic companies are profiled in the report

A. The top companies that hold the market share in infectious disease diagnostic are Abbott Laboratories, Becton Dickinson and Company, BioMerieus SA, Bio-Rad Laboratories, Danaher Corporation, F Hoffman-La Roche, Hologic Inc., Luminex Corporation, Qiagen Inc. and Thermo Fisher Scientific Inc

A. No, there is no value chain analysis provided in the infectious disease diagnostic Market report

A. The key trends in the infectious disease diagnostic market are growth in increase in prevalence of infectious disease such as hepatitis, influenza, COVID-19, and HIV; rise in demand for point-of-care diagnostic test; increase in funding from private & government organizations for the diagnostic service center; and advancement in technology for infectious disease diagnostic.

Allied Market Research Allied Market Research Allied Market Research
RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Infectious Disease Diagnostic Market

Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $6,168
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $10,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Erythropoietin Drugs Market

Global Opportunity Analysis and Industry Forecast, 2021–2028

Published in May 2021

Download Sample

Protein Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2017-2023

Published in Nov 2017

Download Sample

Surgical Equipment Market

Global Opportunity Analysis and Industry Forecast, 2020-2027

Published in Jan 2021

Download Sample

Medical Implant Market

Global Opportunity Analysis and Industry Forecast, 2020–2027

Published in Nov 2020

Download Sample

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers